Quarterly Result12 Nov 2025, 11:44 am
Hester Biosciences Q2 & H1 FY26 Results: Standalone Performance Down, Consolidated Performance Up
AI Summary
Hester Biosciences announced the unaudited financial results for Q2 & H1 FY26. The Poultry Healthcare Division delivered growth, but the Animal Healthcare Division recorded a decline due to delays in government-led immunisation programmes. Despite lower profitability, the company maintained operational discipline and focus on margin protection and cost optimisation. The consolidated results showed an increase in revenues and profit.
Key Highlights
- Standalone Poultry Healthcare Division grew by 18% in Q2 FY26 and 10% in H1 FY26
- Animal Healthcare Division recorded a 50% decline in Q2 FY26 and 41% decline in H1 FY26 due to delays in government-led immunisation programmes
- Consolidated Divisional Product Sales up by 7% in H1 FY26, Profit up by 99%
- Hester Nepal recorded a net loss in Q2 FY26, but expects execution of pending institutional orders to accelerate in the second half of the year
- Hester Africa reported profit growth in Q2 FY26 and H1 FY26, but order flows remain subdued due to delays in project approvals and political transitions